ALB and Hepatic fibrosis: Surrogate markers of liver dysfunction (albumin levels and platelet count) and/or liver fibrosis (LSM) before HCV treatment and LSM regression post-SVR were evaluated to stratify the risk of primary outcomes (LRC or death).